In this ovarian cancer model, EGFR transactivation involves the PAFR activation, the activation of phospholipase C-β, inositol trisphosphate-induced Ca2+ mobilization, activation of the non-receptor tyrosine kinase Src, cleavage and secretion of heparin-binding EGF-like growth factor (HB-EGF) in a matrix metalloproteinase-dependent mechanism (21). This evidence concerns the gene EGFR and ovarian carcinoma.